KITE-197

BIOLOGICAL2 trials

Sponsors

Kite, A Gilead Company

Conditions

Relapsed/Refractory Large B-cell LymphomaSolid and Hematological Malignancies

Phase 1

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma

Active, not recruitingNCT06079164

Kite, A Gilead CompanyRelapsed/Refractory Large B-cell Lymphoma

Start: 2023-11-09End: 2026-07-31Target: 39Updated: 2026-01-08

Unknown Phase

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Enrolling by invitationNCT05041309

Kite, A Gilead CompanySolid and Hematological Malignancies

Start: 2021-12-15End: 2040-12-01Target: 1000Updated: 2026-05-14

Related Papers

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2

Journal of Hematology & Oncology2026-04-27

Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2

Blood2024-11-056 citations